IVF Limit denied as experimental or investigational by UnitedHealthcare?

The UnitedHealthcare Commercial Medical Policy on Infertility Diagnosis, Treatment, and Fertility Preservation governs IVF coverage and refers medical-necessity reviews to the companion Clinical Guideline titled "Fertility Solutions Medical Necessity Clinical Guideline: Infertility." For purposes of this policy, infertility is defined as the inability to achieve a successful pregnancy due to medical, sexual, or reproductive history; failure to achieve pregnancy after 12 months of regular unprotected intercourse (or after 6 months when the female partner meets specified age or risk criteria). Prior authorization is required for IVF and related services and must be submitted via the UnitedHealthcare Provider Portal, and UHC frequently delegates fertility benefit management to Optum (Optum Fertility Solutions), so Optum-managed plans must route prior auth requests and appeals to Optum rather than standard UHC. Quantity limits depend on the member's specific benefit: some plans require Use of a Center of Excellence and apply a lifetime maximum benefit of $25,000 with a $10,000 prescription drug maximum (administered via CVS/Caremark) , while large-group, fully insured California plans are required to cover up to 3 completed oocyte (egg) retrievals and unlimited embryo transfers per plan year . The guideline restricts IVF in specified circumstances: natural cycle IVF is not indicated after 2 failed natural ART cycle attempts; fresh oocyte retrievals are not indicated when previously frozen M2 oocytes or embryos of at least BB grading quality (or genetically normal if tested) are available, although a fresh cycle is indicated when fewer than 20 previously frozen M2 oocytes are available , and additional infertility treatment such as controlled ovarian stimulation, IUI, or ART is not indicated within 6 months of tubal surgery unless additional infertility factors are identified or tubal compromise recurs . Self-injectable infertility drugs are subject to the member-specific benefit/pharmacy benefit administrator, and ART services (IVF, GIFT, ZIFT, PROST, TET) requested for reasons other than infertility are reviewed case-by-case under the member-specific benefit document.

- **Against benefit-exclusion denials in mandate states:** Cite state mandate language; for California, Health and Safety Code §1374.55 requires large group plans issued, amended, or renewed on or after January 1, 2026 to cover diagnosis and treatment of infertility including a maximum of three completed oocyte retrievals with unlimited embryo transfers per ASRM guidelines, and UnitedHealthcare designated this as a benefit standard effective July 1, 2025. - **Against discriminatory definitions of infertility:** UHC's own policy cites ASRM (2021b/2023), ACOG (2019), CDC (2024), and WHO (2022) definitions and recognizes infertility as the inability to achieve pregnancy due to medical, sexual, or reproductive history — not solely the 12-month-intercourse rule ; same-sex couples and single members qualify under this medical-history definition (further, SB 729 prohibits discrimination in coverage and ends the exclusion of LGBTQ+ people in fertility coverage ). - **Against "insufficient prior step therapy" (no IUI tried):** Per ASRM Committee Opinion on diminished ovarian reserve and per UHC's own guideline, IUI is not always required first — history of three failed IUI cycles is one trigger, "unless medically indicated to go straight" to IVF ; document tubal disease, severe male factor (TMSC <5M), advanced maternal age, or DOR (AMH <1.1 ng/mL or FSH ≥10 mIU/mL per ASRM 2020) as a medical indication to bypass IUI. - **Against denial for "embryo banking" or repeat fresh cycle:** Distinguish from banking; per UHC guideline, embryo cryopreservation is a necessary component of elective single embryo transfer and a vital component of pre-implantation genetic testing given the lag time from biopsy to result reporting , and a fresh cycle is indicated when there are fewer than 20 previously frozen M2 oocytes — submit antral follicle count, AMH, and prior-cycle yield to demonstrate the criteria are met. - **Against fertility-preservation denials for iatrogenic infertility (e.g., chemo, GAHT):** Per the Optum Fertility Solutions guideline, fertility preservation is medically necessary for individuals facing gonadotoxic treatment and is indicated for individuals about to undertake gender-affirming hormone therapy (2024 Expert Panel) ; cite ASCO 2018 fertility-preservation guideline and ASRM Ethics Committee Opinion on fertility preservation for medical indications. - **Against wrong-entity / procedural denial:** Confirm which vendor manages the benefit and resubmit; when the plan is Optum-managed, prior authorization requests and appeals must go to Optum, not standard UHC. Request peer-to-peer review with an Optum reproductive endocrinologist within 72 hours of denial. - **Against quantity-limit denials when fewer than 3 retrievals have been used:** Cite ASRM single-embryo-transfer guidance and the plan's own retrieval allowance; large-group fully insured plans must cover up to 3 completed oocyte retrievals and unlimited embryo transfers per plan year, using single embryo transfer when medically appropriate per ASRM — denials before that threshold contradict the policy.

## Why UnitedHealthcare May Deny IVF Cycle Limits as Experimental

An "experimental" or "investigational" denial from UnitedHealthcare in the context of IVF cycle limits most commonly arises when a specific component or adjunct technology proposed within or alongside an IVF cycle is classified by UHC as not having sufficient evidence to be considered standard of care. Examples include certain embryo selection technologies, add-on laboratory procedures, or newer stimulation protocols. Standard IVF itself — egg retrieval, fertilization, and embryo transfer — is not experimental and has decades of published evidence supporting it.

If UHC applied the experimental label to the IVF procedure itself, that is a strong basis for reversal, as IVF is a mainstream medical treatment endorsed by major reproductive medicine organizations. If the label applies to a specific adjunct, the appeal should distinguish the core procedure from the add-on and argue either that the add-on is supported by sufficient evidence or that coverage of the core IVF cycle should not be conditioned on the add-on's status.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair internal review. Request in writing the exact component UHC classified as experimental and the specific evidence criteria used to make that classification.
• External review: Experimental/investigational denials are among the most frequently reversed at external review, because IROs evaluate whether the plan's evidentiary standard is consistent with accepted clinical practice and recognized medical literature. External review is available, generally within four months of final internal denial.
• Clinical urgency: If the time-sensitive nature of your reproductive situation supports expedited review, your physician can certify urgency for a 72-hour external-review decision.

## Documentation to Gather

1. Identification of the denied component — request from UHC in writing the specific procedure code, device, or technique classified as experimental. This is the critical first step. 2. Medical society position statements — your reproductive endocrinologist can provide or cite published positions from the American Society for Reproductive Medicine (ASRM) or other recognized professional organizations regarding the evidence status of the relevant treatment component. 3. Peer-reviewed literature — have your physician identify published, peer-reviewed clinical evidence supporting the use of the specific technique or technology at issue. The appeal does not need to cite statistics; it can reference the existence of published evidence and request that UHC's reviewer weigh it. 4. UHC's evidentiary criteria — request the clinical evidence standards UHC used to classify the item as experimental. These can be compared against the actual evidence base to identify inconsistencies. 5. Physician medical-necessity letter — a letter from your reproductive endocrinologist explaining why the treatment component is clinically indicated for your specific situation and consistent with current reproductive medicine practice.

## Criteria-Mapping Structure

Address the experimental classification directly:

| UHC Criterion for "Not Experimental" | Status for This Treatment | Supporting Source | |---|---|---| | Approval by recognized medical body | ASRM or equivalent position | Cite organization, not statistics | | Peer-reviewed published evidence | Published clinical literature exists | Reference existence; attach if available | | Accepted in clinical practice | Performed at accredited fertility centers | Physician attestation | | FDA clearance (if device-related) | Confirm regulatory status | Device labeling or FDA database |

If the experimental designation applies only to an add-on and not to the core IVF cycle, explicitly request that the core procedure be authorized separately even if the add-on dispute continues.